Company: NCEL
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026428
Chunk: 35

Company: NewcelX Ltd.
Filing Date: 2025-03-31
Form: F-4/A
Chunk 35
---
 cash of NLS and Kadimastem and estimated closing indebtedness of NLS. Based on the cash balance of NLS following its most recent financing transactions from October 2024 and December 2024 (for more information please see “NLS’s Management’s Discussion and Analysis of Financial Condition and Results of Operations — Financing Activities”), the parties currently estimate the fully diluted share split at the Closing will be 80% to Kadimastem shareholders and 20% to NLS shareholders. The Merger has been unanimously approved by both the NLS Board and Kadimastem Board, and has further been approved by the shareholders of Kadimastem. NLS is sending these materials to its shareholders to help them decide how to vote their NLS Common Shares and Preferred Shares, as the case may be, with respect to the matters to be considered at the NLS Meeting. This proxy statement/prospectus and its annexes contain important information about the proposed Merger, Merger Agreement and other matters to be acted upon at the NLS Meeting. You should read this proxy statement/prospectus and its annexes carefully and in their entirety. This proxy statement/prospectus constitutes both a proxy statement and a prospectus of NLS. It is a proxy statement because the NLS Board is soliciting proxies from NLS’s shareholders in connection with the NLS Meeting. It is a prospectus because NLS will issue NLS Common Shares in exchange for outstanding Kadimastem Ordinary Shares in the Merger. This proxy statement/prospectus is not intended to be and is not a prospectus for purposes of Israeli Securities Law, and the ISA has not approved this proxy statement/prospectus. For a more complete description of the Merger, please see the section entitled “ The Merger Proposal (Proposal 1) — The Merger Agreement” in this proxy statement/prospectus. Q.What matters will be considered and voted on at the NLS Meeting? There are 15 matters proposed by the NLS Board, scheduled for a vote at the NLS Meeting: 1.To approve, on an advisory basis, the Merger Agreement. 2.To approve the increase of the share capital of the Company, by way of an ordinary capital increase, by up toOrdinary Shares, and up to a maximum of CHF, to create the required number of the NLS Common Shares to be issued at the effective time of the Merger to the shareholders of Kadimastem in exchange for their Kadimastem